NIEL, BELGIUM, March 28, 2022, eTheRNA Manufacturing, a specialist
RNA process developer and manufacturing member of the Belgian eTheRNA
group, is introducing a new Lipid Nanoparticle (LNP) formulation
development and production service to support the discovery and early
pre-clinical development of RNA-based therapeutics and vaccines.
GENEVA, 23 March 2022 – STALICLA, a Swiss clinical stage biotech
company leading omics-based drug development for patients with
neurodevelopmental disorders (NDDs), announced today the highly
successful completion of the phase 1b trials for its lead drug candidate
STP1. These clinical data clear the way for a first application of
STALICLAís precision medicine discovery platform in autism spectrum
disorders.
MARTINSRIED, Germany and OSAKA, Japan, March 17, 2022 / B3C newswire /
— Coriolis Pharma, a globally operating service provider and one of
the world leaders in formulation research and development of
(bio)pharmaceutical drugs located in Germany, and U-Medico, an
innovative formulation development and biophysical characterisations
service provider located in Japan, today announce a strategic alliance
that includes an equity investment by Coriolis Pharma into U-Medico.
